Selecting a CTMS is a procurement decision. Validating one is a compliance obligation — and they rarely happen on the same timeline, or with the same people in the room.
The GapA vendor's validation package covers the base platform — not your deployment.Your configuration, customizations, data migration, and interfaces to other systems fall outside a vendor's validation summary and require their own risk-based testing.
The RiskMost exposure surfaces after go-live, not during selection.SaaS platforms update on the vendor's schedule. Without change control on your side, a validated state quietly erodes with every release.
Selection committees evaluating clinical trial management software tend to compare the same things: dashboard design, module depth, integration claims, price per user. Somewhere between the demo and the signed order form, a different question gets deferred rather than answered — not whether the platform can do the job, but whether your specific deployment of it can survive a Part 11 inspection. That question doesn't belong to the vendor. It belongs to you.
This isn't an argument against any particular platform. Veeva Vault CTMS, Medidata Rave, OnCore, Oracle's clinical suite, Castor EDC, ClinCapture, TrialMaster, RealTime CTMS, and eClinicalWorks all have legitimate use cases, and the CTMS market has grown accordingly as sponsors look for tools that keep pace with increasingly complex study designs. The gap isn't in the software. It's in what happens — or doesn't — between the purchase order and go-live.
CTMS evaluations are usually run by the people who will use the system day to day, with validation handed off as a downstream task once the contract is signed. That sequencing is understandable, and it's also where most exposure gets built in. We've written more specifically about what regulators actually look for in a compliant CTMS deployment in our breakdown of CTMS compliance features — the short version is that features are a vendor claim, and validation is your evidence.
The Core Strategy: What Validation Actually Requires
A vendor's validation summary documents what the vendor tested on the base platform — not the modules you configured, the fields you customized, or the systems you connected it to. Under a risk-based CSA approach, closing that gap comes down to three areas that consistently get underweighted.
01
Configuration & Electronic Records
Part 11 and Annex 11 don't care which vendor built the audit trail — they care whether it's complete, attributable, and tamper-evident in your live environment. That's a function of how you configured the system, not what the vendor's base validation covered.
Actionable StepGet the vendor's current validation summary and map every module you've configured against it. Anything outside that summary needs its own risk assessment and test evidence.
02
Data Migration & Interfaces
If you're moving off a legacy system or a fragmented set of spreadsheets, the migration needs its own validation — reconciliation, not just a successful import. Every connection to an eTMF, EDC, or safety database is a separate point where data integrity has to be demonstrated, not assumed.
Actionable StepTreat data migration and each system interface as discrete validation activities with their own test scripts, separate from the platform validation itself.
03
Change Control & Periodic Review
SaaS platforms push updates on the vendor's release calendar, not yours. Without a documented process for assessing each release before it reaches production, an organization's validated state can drift out of compliance long before anyone notices — usually surfacing at the next inspection.
Actionable StepAssign clear ownership for periodic review after go-live, and require a GxP impact assessment before any vendor update is accepted into production.
A Note on Platform Choice
Whether you land on Veeva Vault CTMS, Medidata Rave, Oracle's clinical suite, OnCore, Castor EDC, ClinCapture, TrialMaster, RealTime CTMS, or eClinicalWorks, the validation obligation doesn't change with the logo. The platforms differ in configurability, cost, and user experience. They don't differ in what a regulator expects you to demonstrate. If a vendor or an evaluation deck implies otherwise, that's worth a second look before you sign, not after.
The two most common failure points we see in CQV engagements aren't about platform choice at all: change control that never catches up with a SaaS vendor's release cadence, and interface validation that was done once at launch and never revisited as connected systems changed on their own timelines. Our fill-finish case study walks through what lifecycle validation discipline looks like applied to a comparably interconnected, comparably regulated system.
A platform can score perfectly on every feature comparison and still arrive at your first inspection with no evidence that your configuration of it was ever formally tested.
Partner With AVS Life Sciences
Validate the CTMS You've Already Chosen — Or the One You're About To
AVS Life Sciences works alongside sponsors and CDMOs as the validation partner for the systems they choose, using the AVS Lifecycle Readiness Check to surface gaps before a contract is signed and before go-live.
Frequently Asked Questions About Validating a Clinical Trial Management System
No. A vendor's validation summary covers the base platform as tested by the vendor. Your specific configuration, customizations, data migration, and interfaces to other systems need to be validated separately, based on a risk assessment of what's actually different about your deployment.
Selection is a procurement decision based on features, usability, and cost. Validation is the documented evidence that your specific instance of the system performs reliably and meets GxP requirements for your intended use. Treating selection sign-off as validation sign-off is a common source of inspection findings.
No. Regulatory expectations around electronic records, electronic signatures, and audit trails are the same regardless of platform. What varies is how much configuration work is required to meet them, which is worth weighing during selection but doesn't change the underlying obligation.
SaaS-delivered CTMS platforms update on the vendor's release schedule, not the sponsor's. Without a change control process assessing each update's GxP impact before it reaches production, an organization's validated state can drift out of compliance well before anyone notices.
A structured self-audit tool AVS developed to help sponsors and CDMOs identify validation gaps at two key moments: before signing with a CTMS vendor, and before go-live.
AVS Life Sciences applies the same lifecycle discipline to CTMS validation as it does to facility and equipment qualification — treating validation as an ongoing program, not a one-time event tied to go-live.
No. AVS provides commissioning, qualification, and validation (CQV) services for the systems sponsors and CDMOs already use or are evaluating, including CTMS platforms. AVS validates and integrates the software clients choose rather than competing with the vendors who build it.
